The Innovative Medicine Initiative (IMI)-funded Zoonoses Anticipation and Preparedness Initiative (ZAPI) project was designed as a new consortium in 2014 and was launched in March 2015, almost 5 years before the Covid-19 outbreak impact started to affect our lives everywhere on the globe. This IMI project call was designed by the animal health industry and human pharma industry to deliver practical solutions to address the medical needs associated with the emergence of zoonotic infectious diseases. More than 70% of zoonotic diseases are originating from viral pathogens harboured by animals and new, highly scalable technologies, are necessary to address such global needs. Jean-Christophe Audonnet at Boehringer Ingelheim discusses how achieving these huge needs, especially for human and veterinary vaccines, impose to radically revisit the classical manufacturing and regulatory pathways.